These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23714563)

  • 1. Risk stratification of rhabdomyosarcoma: a moving target.
    Arndt CA
    Am Soc Clin Oncol Educ Book; 2013; ():415-9. PubMed ID: 23714563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram.
    De Salvo GL; Del Bianco P; Minard-Colin V; Chisholm J; Jenney M; Guillen G; Devalck C; Van Rijn R; Shipley J; Orbach D; Kelsey A; Rogers T; Guerin F; Scarzello G; Ferrari A; Cesen Mazic M; Merks JHM; Bisogno G;
    Cancer; 2024 Jul; 130(13):2351-2360. PubMed ID: 38400828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnostics in the management of rhabdomyosarcoma.
    Arnold MA; Barr FG
    Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
    Anderson JR; Barr FG; Hawkins DS; Parham DM; Skapek SX; Triche TJ
    J Clin Oncol; 2010 Oct; 28(29):e587-8; author reply e589-90. PubMed ID: 20697086
    [No Abstract]   [Full Text] [Related]  

  • 16. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
    Harel M; Ferrer FA; Shapiro LH; Makari JH
    Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
    Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
    Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.